Core Points - Rosen Law Firm is reminding purchasers of Skye Bioscience, Inc. securities of the January 16, 2026 lead plaintiff deadline for a class action lawsuit [1][2] - Investors who purchased Skye securities between November 4, 2024, and October 3, 2025, may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [1][4] Company Details - The lawsuit alleges that Skye's defendants made materially false and misleading statements regarding the effectiveness of nimacimab, overstating its clinical, regulatory, and commercial prospects [4] - The firm has a strong track record in securities class actions, having achieved significant settlements, including over $438 million for investors in 2019 [3]

Core Points - Rosen Law Firm is reminding investors who purchased Perrigo Company plc securities between February 27, 2023, and November 4, 2025, of the January 16, 2026, lead plaintiff deadline for a class action lawsuit [1] - Investors may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [1] Company Details - The lawsuit alleges that Perrigo made materially false and misleading statements regarding its infant formula business acquired from Nestlé, including significant underinvestment in maintenance and the need for substantial capital expenditures [4] - The lawsuit claims that Perrigo's financial results, including earnings and cash flow, were overstated due to these issues, leading to misleading positive statements about the company's business and prospects [4] Legal Process - To join the class action, investors can submit a form or contact the law firm directly, with a lead plaintiff needing to move the court by January 16, 2026 [2][5] - The Rosen Law Firm emphasizes the importance of selecting qualified counsel with a successful track record in securities class actions [3]

Core Viewpoint - Rosen Law Firm is reminding investors who purchased securities of Jayud Global Logistics Ltd. during the specified Class Period of the upcoming lead plaintiff deadline on January 20, 2026 [1] Group 1: Class Action Details - Investors who purchased Jayud securities between April 21, 2023, and April 30, 2025, may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2] - A class action lawsuit has already been filed, and interested parties can join by contacting the firm or visiting their website [3][6] - The lead plaintiff must file a motion with the Court by January 20, 2026, to represent other class members [3] Group 2: Law Firm Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved the largest securities class action settlement against a Chinese company at that time [4] - The firm was ranked No. 1 by ISS Securities Class Action Services for the number of settlements in 2017 and has consistently ranked in the top 4 since 2013, recovering hundreds of millions for investors [4] - In 2019, the firm secured over $438 million for investors, and its founding partner was recognized as a Titan of Plaintiffs' Bar by Law360 in 2020 [4] Group 3: Case Allegations - The lawsuit alleges that Jayud made materially false and misleading statements and failed to disclose critical information, including involvement in a fraudulent stock promotion scheme and insider trading activities [5] - Specific allegations include the use of social media misinformation, offshore accounts for share dumping, and omission of risks related to false rumors and artificial trading activity [5]

Core Viewpoint - Rosen Law Firm is investigating potential securities claims on behalf of shareholders of Agilon Health, Inc. due to allegations of materially misleading business information issued by the company [1]. Group 1: Company Performance and Issues - On August 4, 2025, Agilon Health reported its second quarter results, indicating that industry headwinds were more severe than previously anticipated, leading to the suspension of its full-year 2025 financial guidance [3]. - Following the announcement, Agilon Health's stock experienced a significant decline of 51.5% on August 5, 2025 [3]. Group 2: Legal Actions and Investor Rights - Investors who purchased Agilon Health securities may be eligible for compensation through a class action lawsuit without any out-of-pocket fees, as the Rosen Law Firm is preparing to seek recovery of investor losses [2]. - The Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a successful track record in securities class actions, highlighting its own achievements in recovering substantial amounts for investors [4].

Core Viewpoint - Rosen Law Firm is investigating potential securities claims on behalf of shareholders of Western Alliance Bancorporation due to allegations of materially misleading business information [1] Group 1: Legal Actions and Stock Performance - Western Alliance Bancorporation disclosed a lawsuit against Cantor Group V LLC for fraud related to collateral loans, resulting in a 10.88% stock price drop on October 16, 2025 [3] Group 2: Class Action Information - Investors who purchased Western Alliance Bancorporation securities may be entitled to compensation through a class action without any out-of-pocket fees, with Rosen Law Firm preparing to seek recovery of investor losses [2] Group 3: Rosen Law Firm's Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved the largest securities class action settlement against a Chinese company and being ranked No. 1 for settlements in 2017 [4] - The firm has recovered hundreds of millions of dollars for investors, securing over $438 million in 2019 alone [4]

Core Points - Rosen Law Firm is reminding purchasers of Skye Bioscience, Inc. securities of the lead plaintiff deadline for a class action lawsuit, which is January 16, 2026 [1] - Investors who purchased Skye securities during the specified Class Period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2] - A class action lawsuit has already been filed, and interested parties can join by contacting Rosen Law Firm [3] Case Details - The lawsuit alleges that during the Class Period, defendants made materially false and misleading statements regarding Skye's business and prospects, particularly concerning the effectiveness of nimacimab [5] - Specific claims include that nimacimab was less effective than represented, leading to overstated clinical, regulatory, and commercial prospects [5] - The lawsuit asserts that when the true details became known, investors suffered damages [5] Rosen Law Firm's Credentials - Rosen Law Firm emphasizes the importance of selecting qualified counsel with a successful track record in securities class actions [4] - The firm has achieved significant settlements, including the largest securities class action settlement against a Chinese company and has consistently ranked highly in securities class action settlements [4] - In 2019, the firm secured over $438 million for investors, showcasing its capability in recovering funds for clients [4]

Core Viewpoint - Rosen Law Firm is reminding investors who purchased common stock of StubHub Holdings, Inc. about the upcoming lead plaintiff deadline for a class action lawsuit related to the company's September 2025 IPO [1]. Group 1: Class Action Details - Investors who bought StubHub common stock may be eligible for compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and interested parties must move the Court to serve as lead plaintiff by January 23, 2026 [3]. - The lawsuit claims that the Registration Statement was materially false and misleading, omitting significant information about changes in payment timing to vendors and its adverse impact on free cash flow [5]. Group 2: Rosen Law Firm's Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved the largest securities class action settlement against a Chinese company and being ranked No. 1 for settlements in 2017 [4]. - The firm has recovered hundreds of millions of dollars for investors, including over $438 million in 2019 alone [4]. - Many attorneys at Rosen Law Firm have received recognition from Lawdragon and Super Lawyers, highlighting the firm's expertise in this area [4].

Core Viewpoint - Rosen Law Firm is reminding investors who bought or sold Cepton, Inc. (NASDAQ: CPTN) common stock between July 29, 2024, and January 6, 2025, of the December 8, 2025, deadline to become a lead plaintiff in a class action lawsuit [1]. Group 1: Class Action Details - Investors who purchased or sold Cepton common stock during the specified Class Period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - To participate in the class action, interested parties can visit the provided link or contact Phillip Kim, Esq. for more information [3][6]. - A lead plaintiff is required to file a motion with the Court by December 8, 2025, to represent other class members in the litigation [3]. Group 2: Law Firm Credentials - Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a successful track record in securities class actions, highlighting its own achievements in this area [4]. - The firm has secured significant settlements for investors, including over $438 million in 2019 and has been ranked highly for its performance in securities class action settlements [4]. Group 3: Case Allegations - The lawsuit alleges that during the Class Period, Cepton's management made materially false and misleading statements regarding the company's business and operations [5]. - Specific allegations include the failure to disclose a credible third-party bid valuing Cepton at more than double the Koito Acquisition and the Board's lack of meaningful exploration of this offer [5]. - As a result, shareholders were deprived of the opportunity to make an informed decision regarding the Koito Acquisition [5].

Core Viewpoint - Rosen Law Firm is investigating potential securities claims on behalf of shareholders of Western Alliance Bancorporation due to allegations of materially misleading business information [1] Group 1: Legal Actions and Stock Impact - Western Alliance Bancorporation initiated a lawsuit against Cantor Group V LLC for fraud related to collateral loans, resulting in a 10.88% stock price drop on October 16, 2025 [3] Group 2: Class Action Information - Investors who purchased Western Alliance Bancorporation securities may be entitled to compensation through a class action without any out-of-pocket fees, with Rosen Law Firm preparing to seek recovery of investor losses [2] Group 3: Rosen Law Firm's Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved the largest securities class action settlement against a Chinese company at the time and being ranked No. 1 for the number of settlements in 2017 [4]

Core Viewpoint - Rosen Law Firm is investigating potential securities claims on behalf of shareholders of Tandem Diabetes Care, Inc. due to allegations of materially misleading business information issued by the company [1]. Group 1: Company Information - Tandem Diabetes Care, Inc. issued a press release on August 7, 2025, announcing a voluntary medical device correction for select t:slim X2 insulin pumps, addressing a potential speaker-related issue that could lead to insulin delivery discontinuation [3]. - Following the announcement, Tandem Diabetes' stock experienced a significant decline of 19.9% on the same day [3]. Group 2: Legal Actions - Investors who purchased Tandem Diabetes Care securities may be eligible for compensation through a class action lawsuit, with no out-of-pocket fees due to a contingency fee arrangement [2]. - The Rosen Law Firm is preparing a class action to seek recovery of investor losses related to the misleading information [2]. Group 3: Rosen Law Firm Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved the largest securities class action settlement against a Chinese company and being ranked No. 1 for the number of settlements in 2017 [4]. - The firm has recovered hundreds of millions of dollars for investors, securing over $438 million in 2019 alone [4].